Evidence map›Paper›PMID 26041338›Full record

ArticlePsychopharmacology2015

Role of 5-HT₂C receptors in effects of monoamine releasers on intracranial self-stimulation in rats.

Clayton T Bauer, Matthew L Banks, Bruce E Blough, S Stevens Negus

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The serotonin 5-HTJournal of psychopharmacology (Oxford, England) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Clayton T BauerDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th St., PO Box 980613, Richmond, VA, 23298, USA.
Matthew L Banks
Bruce E Blough
S Stevens Negus
Virginia Commonwealth University · USRTI International · US

Funding

Synthetic cathinones: a new class of illicit drugs affecting DAT & SERTR01DA033930 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ELTIT, JOSE MIGUEL, GLENNON, RICHARD A · 2012 to 2016
$2.7M
Mechanisms of Psychostimulant AbuseF30DA034478 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAUER, CLAYTON THOMAS · 2013 to 2015
$78k
NIDA NIH HHS F30 DA034478NIDA NIH HHS F30DA034478NIDA NIH HHS R01-DA012790NIDA NIH HHS R01 DA033930NIDA NIH HHS R01-DA033930
6 · The paper itself

Abstract

rationaleMany monoamine releasers are abused by humans and produce abuse-related facilitation of intracranial self-stimulation (ICSS) in rats. Facilitation of ICSS in rats can be limited by monoamine releaser-induced serotonin (5-HT) release, but receptors that mediate 5-HT effects of monoamine releasers are unknown.

objectivesThe aim of this study is to investigate whether 5-HT2C receptor activation is necessary for rate-decreasing effects produced in an ICSS procedure in rats by the 5-HT-selective monoamine releaser fenfluramine and the non-selective releasers napthylisopropylamine (PAL-287) and (+)-3,4-methylenedioxymethamphetamine ((+)-MDMA).

methodsAdult male Sprague-Dawley rats with electrodes implanted in the medial forebrain bundle were trained to lever press for brain stimulation under a "frequency-rate" ICSS procedure. Effectiveness of the 5-HT2C antagonist SB 242,084 was evaluated to block rate-decreasing effects produced by (1) the 5-HT2C agonist Ro 60-0175, (2) the 5-HT-selective releaser fenfluramine, and (3) the mixed-action dopamine (DA)/norepinephrine (NE)/5-HT releasers PAL-287 (1.0-5.6 mg/kg) and (+)-MDMA (1.0-3.2 mg/kg). For comparison, effectiveness of SB 242,084 to alter rate-decreasing effects of the kappa-opioid receptor agonist U69,593 and rate-increasing effects of the DA>5-HT releaser amphetamine was also examined.

resultsSB 242,084 pretreatment blocked rate-decreasing effects of Ro 60-0175 and fenfluramine, but not the rate-decreasing effects of U69,593 or the rate-increasing effects of amphetamine. SB 242,084 blunted the rate-decreasing effects and enhanced expression of rate-increasing effects of PAL-287 and (+)-MDMA.

conclusionsThese data suggest that 5-HT2C receptor activation contributes to rate-decreasing effects that are produced by selective and mixed-action 5-HT releasers in rats and that may oppose and limit the expression of abuse-related ICSS facilitation by these compounds.

Indexed as

Adrenergic Uptake InhibitorsAminopyridinesAnimalsBenzeneacetamidesBiogenic MonoaminesConditioning, OperantElectrodes, ImplantedFenfluramineIndolesMaleN-Methyl-3,4-methylenedioxyamphetaminePyrrolidinesRatsRats, Sprague-DawleyReceptor, Serotonin, 5-HT2CReceptors, Opioid, kappa6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indolineAdrenergic Uptake InhibitorsAminopyridinesBenzeneacetamidesBiogenic MonoaminesFenfluramineIndolesN-Methyl-3,4-methylenedioxyamphetaminePyrrolidinesReceptor, Serotonin, 5-HT2CReceptors, Opioid, kappaSelective Serotonin Reuptake InhibitorsSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsU 69593

Identifiers

PMID26041338
PMCPMC4536134
OpenAlexW616530852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.